News
PBYI
8.11
+5.74%
0.44
Weekly Report: what happened at PBYI last week (0615-0619)?
Weekly Report · 5d ago
Puma Biotechnology Shareholders Back Governance, Reject Warrant Extension
TipRanks · 06/16 20:40
Puma Biotechnology shareholders reject extension of CEO Auerbach warrant term
PUBT · 06/16 20:08
Puma Bio director Dorval Allison disposes of 11,610 shares for $83,586.02
PUBT · 06/16 00:09
Weekly Report: what happened at PBYI last week (0608-0612)?
Weekly Report · 06/15 09:04
Weekly Report: what happened at PBYI last week (0601-0605)?
Weekly Report · 06/08 09:04
Puma Biotechnology grants inducement RSUs covering 7,000 shares to new hires
PUBT · 06/03 21:00
PUMA BIOTECHNOLOGY REPORTS INDUCEMENT AWARDS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 06/03 21:00
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Barchart · 06/03 16:00
Weekly Report: what happened at PBYI last week (0525-0529)?
Weekly Report · 06/01 09:05
Weekly Report: what happened at PBYI last week (0518-0522)?
Weekly Report · 05/25 09:05
Puma Biotechnology Lifts Outlook Despite Q1 Setback
TipRanks · 05/20 04:13
Weekly Report: what happened at PBYI last week (0511-0515)?
Weekly Report · 05/18 09:05
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
Simply Wall St · 05/15 11:52
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
Simply Wall St · 05/11 13:16
Weekly Report: what happened at PBYI last week (0504-0508)?
Weekly Report · 05/11 09:05
Puma Biotechnology (PBYI) Net Margin Steady At 13.6% Challenges Bearish Earnings Narratives
Simply Wall St · 05/09 00:55
Puma Biotechnology Raises Outlook Despite Q1 Reset
TipRanks · 05/09 00:20
Puma (PBYI) Q1 2026 Earnings Call Transcript
The Motley Fool · 05/08 20:14
Puma forecasts $202M-$206M in 2026 NERLYNX net product revenue while planning alisertib dose escalation and new Lung2 trial
Seeking Alpha · 05/08 13:47
More
Webull provides a variety of real-time PBYI stock news. You can receive the latest news about Puma Biotechnology Inc through multiple platforms. This information may help you make smarter investment decisions.
About PBYI
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of products to enhance cancer care. The Company is commercializing NERLYNX, an oral version of neratinib, for the treatment of certain HER2-positive breast cancers. NERLYNX is approved in the United States for two indications: the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer following adjuvant trastuzumab-based therapy and for use in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. The Company is focused on the global development and commercialization of alisertib. Alisertib is a selective, small-molecule inhibitor of Aurora Kinase A that is designed to disrupt mitosis, leading to apoptosis of rapidly proliferating tumor cells.